Nuvalent, Inc.

NASDAQ:NUVL

Biotechnology

Healthcare
$123.96 -0.02%

-$0.03 today

Market cap
$9.13B
Beta
1.15
P/E (TTM)
-21.6
EPS (TTM)
-$5.72
52W Low $71.13High $123.62

Volume 0.00M

Average 1.91M

NUVL Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Nuvalent, Inc.NASDAQ: NUVL

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization outflow grows to $0

Q1 FY2026 depreciation & amortization was $0, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $0.

Context

  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Depreciation & Amortization vs competitors

How NUVL compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
NUVL Competitors
Depreciation & Amortization for NUVL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JAZZJazz Pharmaceuticals plcLTM Sep 2026$718.57M USD+4.8%+3.4%15.2%
PCVXVaxcyte, Inc.LTM Jun 2026$26.8M USD+40.0%+38.0%—
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$26.62M USD+11.3%+28.7%5.9%
CRSPCRISPR Therapeutics AGLTM Sep 2026$18.5M USD-0.9%-6.9%73.5%
CYTKCytokinetics, IncorporatedLTM Jun 2026$12.55M USD+33.8%+20.3%17.7%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$9.94M USD+16.8%+27.2%1.3%
ABVXAbivax S.A.FY2025€1.07M EUR-2.5%+30.3%—
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$1.02M USD-29.4%-7.2%0.4%
NUVLNuvalent, Inc.LTM Mar 2026$0 USD———
Peer median (excluding NUVL) —+8.0%+23.8%10.6%

Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(46.34M)(81.85M)(126.22M)(260.76M)(425.38M)
Depreciation & Amortization215K(373K)000
Deferred Income Tax(215K)(5.74M)000
Stock-Based Compensation3.55M10.33M25.56M60.58M86.5M
Change in Working Capital1.94M6.93M11.03M11.84M19.21M
Accounts Receivables00000
Inventory00000
Accounts Payables1.64M4.21M2.17M(4.05M)24.6M
Other Working Capital300K2.72M8.86M15.89M(5.39M)
Other Non-Cash Items846K5.74M(10.11M)3.27M44.46M
Operating Cash Flow(40M)(64.97M)(99.74M)(185.06M)(275.21M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments(221.04M)(212.92M)(459.49M)(1.02B)(1.06B)
Sales of Investments1.02M202.25M315.96M451.45M933.69M
Other Investing Activities00000
Investing Cash Flow(220.03M)(10.67M)(143.53M)(573.51M)(124.08M)
Debt Repayment284K0000
Common Stock Issued177.27M248.63M324.3M569.99M515.34M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.98M)286K12.55M(1.11M)0
Financing Cash Flow318.22M248.92M336.85M568.88M515.34M
Effect of Forex Changes00000
Net Change in Cash58.19M173.28M93.58M(189.7M)116.05M
Free Cash Flow(40M)(64.97M)(99.74M)(185.06M)(275.21M)

Nuvalent, Inc.

NASDAQ:NUVL

Intrinsic Alpha fair value

Locked

Current Price

$123.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.